Solvay says study shows fenofibrate cuts risk of vision loss in type 2 diabetes

BRUSSELS (Thomson Financial) - Belgian chemicals and pharmaceuticals group Solvay SA said a clinical study showed that its fenofibrate drug reduces the need for treatment for vision loss in patients with type 2 diabetes.

The study revealed that the drug reduced the need for laser therapy for diabetic eye disease by more than 30 pct.

In an additional study of around 1,000 patients with pre-existing eye disease, fenofibrate showed a reduction in the disease's progression.

Solvay said the study also showed that the drug "significantly decreased" the risk of non-traumatic amputations.

Solvay acquired fenofibrate through the acquisition of France's Fournier in 2005.

nina.chestney@thomson.com nc/slj COPYRIGHT Copyright Thomson Financial News Limited 2007. All rights reserved.

The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.